Novel small molecule αv integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 959-968

  Kerr, Janet S ^a   Wexler, Roseanne S ^a   Mousa, Shaker A ^a   Robinson, Candy S ^a   Wexler, Eric J ^a   Mohamed, Seema ^a   Voss, Matthew E ^a   Devenny, James J ^a   Czerniak, Philip M ^a   Gudzelak Jr , Andrew ^a   Slee, Andrew M ^a  

^a DUPONT COMPANY   (United States)

Author keywords

v integrin; v 3; Anti angiogenic; Endothelium; Flavopiridol; TNP470; Tumor

Indexed keywords

3 [[[1 [3 (1H IMIDAZOL 2 YLAMINO)PROPYL] 1H INDAZOL 5 YL]CARBONYL]AMINO] N (MESITYLSULFONYL)ALANINE; ALPHA V INTEGRIN ANTAGONIST; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FLAVOPIRIDOL; FUMAGILLOL CHLOROACETYLCARBAMATE; HEMOGLOBIN; INTEGRIN; SD 983; SG 545; UNCLASSIFIED DRUG; XJ 735; XL 123; XT 199;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDAZOLES; INTEGRIN ALPHAV; INTEGRINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033065782     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Folkman J and Shing Y: Angiogenesis. J Biol Chem 276: 10931-10934, 1992.
2. Klagsbrun M and D'Amore PA: Regulators of angiogenesis. Annu Rev Physiol 53: 217-239, 1991.
3. Brem S, Folkman J, Finkelstein D, et al: Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 36: 2807-2812, 1976.
4. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
5. Holmgren LM, O'Reilly MS, Folkman J: Dormancy of micrometatases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995.
6. Parangi S, O'Reilly M.S, Christofori G, et al: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93: 2002-2007, 1996.
7. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Path 147: 9-19, 1995.
8. Gasparini G and Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new diagnostic tool. J Clin Oncol 13: 765-782, 1995.
9. Craft PS and Harris AL: Clinical prognostic significance of tumour angiogenesis. Ann Oncol 5: 305-311, 1994.
10. Brooks PC: Role of integrins in angiogenesis. Europ J Cancer 32A: 2423-2429, 1996.
11. Bischoff J: Perspectives Series: Cell adhesion in vascular biology. J Clin Invest 99: 373-376, 1997.
12. Samanen J, Jonak Z, Rieman D, et al: Vascular indications for the integrin αν antagonists. Curr Pharmaceut. Design 3: 545-584, 1997.
13. Clarke EA and Brugge JS: Integrins and signal transduction pathways: the road taken. Science 268; 233-239, 1995.
14. Cheresh DA: Structural and biological properties of integrin-mediated cell adhesion. Clin Lab Med 12: 217-236, 1992.
15. Brooks PC, Clark RAF, Cheresh DA: Requirement of vascular integrin υνβ3 for angiogenesis. Science 264: 569-571, 1994.
16. Brooks PC, Mongomery AMP, Rosenfeld, M et al: Integrin ανβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994.
17. Varner JA and Cheresh DA: Tumor angiogenesis and the role of vascular cell integrin ανβ3. In: Important Advances in Oncology (ID Goldberg and EM Rosen, eds) New York, Lippincott-Raven Publishing Co. 1996, pp69-87.
18. Friedlander M, Brooks PC, Shaffer, R, et al: Definition of two angiogenic pathways by distinct αν integrins. Science 264: 1500-1502, 1994.
19. Brooks PC, Stromblad, S, Klemke R, et al: Antiintegrin ανβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822, 1995.
20. Corron CP, Meyer DM, Peff JA, et al: A peptomimetic antagonist of the integrin ανβ3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 58: 1930-1935, 1998.
21. Mousa SA, Forsythe M, Wityak J, et al: Intravenous and oral antiplateletlantithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist. J Cardiovasc Pharm 31: 441-448, 1998.
22. Luna J, Tobe T, Mousa SA, et al: Antagonists of integrin ανβ3 inhibit retinal neovascularization in a murine model. Lab Invest 75: 563-573, 1996.
23. Passaniti A, Taylor RM, Pili R et al: Methods in laboratory investigation. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 67: 519-528, 1992.
24. Dykes DJ, Abbott BJ, Mayo JG, et al: Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol Basel Karger 42: 1-22, 1992.
25. Weidner N, Semple JP, Welch WR et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Eng J Med 324: 1-8, 1991.
26. Twardowski P and Gradishar WJ: Clinical trials of antiangiogenic agents. Curr Opinion in Oncol 9: 584-589, 1997.
27. Voest EE: Inhibitors of angiogenesis in a clinical perspective. Anti-Cancer Drugs 7: 723-727, 1996.
28. Robinson C, Slee AM, Kerr JS: Flavopiridol as an anti-angiogenic agent. FASEB J 11: A63, 1997.
29. Sedlacek HH, Czech J, Naik R, et al: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9: 1143-1168, 1996.
30. O'Reilly MS, Boehm T, Shing T, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
31. Pluda JM: Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Sem Oncol 24: 203-218, 1997.
32. Sin Y, Meng L, Wang MQW, et al: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine amino-peptidase, MetAP-2. Proc Natl Acad Sci USA, 94: 6099-6103, 1997.
33. Griffith EC, Su Z, Turk BE, et al: Methionine aminopeptidase (type 2) is the common target for antiangiogenesis inhibitors AGM-1470 and ovalicin. Chem & Biol 4: 461-471, 1997.